AMRX
NASDAQ
US
Amneal Pharmaceuticals, Inc. - Class A Common Stock
$12.48
▼ $-0.23
(-1.81%)
Vol 1.4M
9
Quality Score
ok
Deep Check
1/5
fail
Rev ✓
NI ✗
>IPO ✗
Mkt Cap
$4.0B
P/E
671.4
ROE
-34.9%
Margin
0.2%
D/E
13657.60
Beta
1.37
52W
$7–$13
Wall Street Consensus
11 analysts · Apr 20262
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
About Amneal Pharmaceuticals, Inc. - Class A Common Stock
Ameri Holdings, Inc. (AMRX) - це компанія, що спеціалізується на наданні послуг з інформаційних технологій, а не фармацевтична компанія. Вона зосереджена на рішеннях для цифрової трансформації, включаючи ERP, хмарні обчислення та аналітику даних. Через відсутність діяльності у фармацевтичній галузі, AMRX не має позиції або конкурентних переваг на цьому ринку.
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.19 | $0.21 | +$0.02 |
| Sep 2025 | $0.14 | $0.17 | +$0.03 |
| Jun 2025 | $0.18 | $0.25 | +$0.07 |
| Mar 2025 | $0.15 | $0.21 | +$0.06 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $730.5M | $695.4M | $724.5M | $784.5M | $814.3M |
| Net Income | — | -$31.1M | $12.2M | $22.4M | $2.4M | $35.1M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -34.9% | -34.9% | -34.9% | -34.9% | -34.9% |
| P/E (TTM) | 751.28 | 875.70 | 965.97 | 1006.91 | 639.38 | 671.35 |
| Net Margin | 3.1% | 0.1% | 0.1% | 0.1% | 0.2% | 0.2% |
| Gross Margin | 39.5% | 37.7% | 37.7% | 37.7% | 36.8% | 36.8% |
| D/E Ratio | — | 13657.60 | 13657.60 | 13657.60 | 13657.60 | 13657.60 |
| Current Ratio | 1.43 | 1.43 | 1.43 | 1.43 | 2.13 | 2.13 |
Key Ratios
ROA (TTM)
0.2%
P/S (TTM)
1.35
P/B
140.7
EPS (TTM)
$0.01
CF/Share
$1.76
Rev Growth 3Y
+10.1%
52W High
$13.01
52W Low
$6.69
$6.69
52-Week Range
$13.01
Financial Health
Free Cash Flow
$84.1M
Net Debt
$2.4B
Cash
$282.0M
Total Debt
$2.7B
As of Dec 31, 2025
How does AMRX compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
AMRX valuation vs Pharmaceuticals peers
P/E ratio
671.4
▲
2090%
above
peers
(30.7)
vs Peers
vs Industry
Pricier
P/S ratio
1.4
▼
80%
below
peers
(6.7)
vs Peers
vs Industry
Undervalued
P/B ratio
140.7
▲
2596%
above
peers
(5.2)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
AMRX profitability vs Pharmaceuticals peers
ROE
-34.9%
▼
34%
below
peers
(-26.1%)
vs Peers
vs Industry
Weak
Net margin
0.2%
▲
114%
above
peers
(-1.5%)
vs Peers
vs Industry
Below avg
Gross margin
36.8%
▼
59%
below
peers
(88.9%)
vs Peers
vs Industry
Weak
ROA
0.2%
▲
102%
above
peers
(-9.5%)
vs Peers
vs Industry
Below avg
AMRX financial health vs Pharmaceuticals peers
D/E ratio
13657.6
▲
49836%
above
peers
(27.4)
vs Peers
vs Industry
High debt
Current ratio
2.1
▼
39%
below
peers
(3.5)
vs Peers
vs Industry
Low liquidity
Beta
1.4
▲
133%
above
peers
(0.6)
vs Peers
vs Industry
More volatile
AMRX fundamentals radar
AMRX
Peer median
Industry
AMRX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio